Payment overview · 2025
General Payments
$169.28
9 reported records · 4 companies
Healthcare provider profile · identity verified
Darius Gharib, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ENCINO, CA · NPI 1013929918
Verified facts
What the public records show
CMS Open Payments records show Darius Gharib, M.D. received $169.28 in general payments during 2025 across 9 reported records.
Exact Sciences Corporation accounted for 38.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Leqvio, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LEQVIO as an associated drug or biological on 126702 records involving 33819 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Leqvio by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $64.77 | 38.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.85 | 28.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.44 | 23.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.22 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $169.28 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $64.77 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.85 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $40.44 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $40.44 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 33 | exact normalized | Medicare Part D |
| LEQVIO leqvio |
2025 | Leqvio | 2024 | 50 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 153 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
33 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
153 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | LEQVIO open payments reported associated product |
CMS Open Payments — General Payments 126702 supporting records · 33819 recipient NPIs · example record 1200004747 |
Leqvio · 2024 Exact normalized brand match · 1 Part D row |
50 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 820 | 192 |
| Atorvastatin Calcium | Atorvastatin Calcium | 556 | 128 |
| Ozempic | Semaglutide | 423 | 74 |
| Metformin Hcl Er | Metformin Hcl | 374 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 78 |
| Losartan Potassium | Losartan Potassium | 304 | 58 |
| Ezetimibe | Ezetimibe | 287 | 73 |
| Prolia | Denosumab | 285 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 262 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 54 |
| Jardiance | Empagliflozin | 218 | 43 |
| Omeprazole | Omeprazole | 212 | 60 |
| Farxiga | Dapagliflozin Propanediol | 210 | 43 |
| Vascepa | Icosapent Ethyl | 206 | 47 |
| Azithromycin | Azithromycin | 195 | 123 |
| Famotidine | Famotidine | 170 | 49 |
| Alprazolam | Alprazolam | 168 | 32 |
| Gabapentin | Gabapentin | 166 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 39 |
| Potassium Chloride | Potassium Chloride | 161 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 157 | 41 |
| Meloxicam | Meloxicam | 154 | 54 |
| Linzess | Linaclotide | 153 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 151 | 43 |
| Finasteride | Finasteride | 150 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 149 | 41 |
| Lorazepam | Lorazepam | 147 | 24 |
| Mounjaro | Tirzepatide | 119 | 21 |
| Pregabalin | Pregabalin | 117 | 31 |
| Dexlansoprazole Dr | Dexlansoprazole | 114 | 22 |
| Donepezil Hcl | Donepezil Hcl | 114 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 22 |
| Sertraline Hcl | Sertraline Hcl | 111 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 29 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 102 | 19 |
| Furosemide | Furosemide | 99 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 93 | 32 |
| Metformin Hcl | Metformin Hcl | 92 | 16 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 88 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 81 | 26 |
| Clonazepam | Clonazepam | 77 | 13 |
| Repatha Sureclick | Evolocumab | 77 | 14 |
| Allopurinol | Allopurinol | 76 | 15 |
| Glipizide Er | Glipizide | 75 | 16 |
| Trazodone Hcl | Trazodone Hcl | 75 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 18 |
| Alendronate Sodium | Alendronate Sodium | 73 | 20 |
| Carvedilol | Carvedilol | 73 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 20 |
| Synthroid | Levothyroxine Sodium | 71 | 17 |
| Tramadol Hcl | Tramadol Hcl | 69 | 18 |
| Januvia | Sitagliptin Phosphate | 67 | 15 |
| Ondansetron Odt | Ondansetron | 65 | 29 |
| Atenolol | Atenolol | 63 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 14 |
| Bupropion Xl | Bupropion Hcl | 61 | 13 |
| Cefdinir | Cefdinir | 60 | 43 |
| Doxepin Hcl | Doxepin Hcl | 60 | 17 |
| Simvastatin | Simvastatin | 60 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 55 | 14 |
| Lidocaine | Lidocaine | 53 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 53 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 21 |
| Eliquis | Apixaban | 52 | 16 |
| Memantine Hcl | Memantine Hcl | 52 | 12 |
| Leqvio | Inclisiran Sodium | 50 | 24 |
| Methimazole | Methimazole | 50 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 49 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 13 |
| Methylprednisolone | Methylprednisolone | 48 | 46 |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Myrbetriq | Mirabegron | 47 | 11 |
| Calcitriol | Calcitriol | 46 | suppressed |
| Lisinopril | Lisinopril | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 15 |
| Dutasteride | Dutasteride | 44 | 16 |
| Gemtesa | Vibegron | 44 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 43 | 14 |
| Irbesartan | Irbesartan | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | suppressed |
| Trulicity | Dulaglutide | 38 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 34 |
| Kerendia | Finerenone | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | suppressed |
| Methadone Hcl | Methadone Hcl | 35 | suppressed |
| Restasis | Cyclosporine | 35 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 34 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Creon | Lipase/Protease/Amylase | 33 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Repaglinide | Repaglinide | 31 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 31 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Prednisone | Prednisone | 28 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Cyclosporine | Cyclosporine | 22 | suppressed |
| Estradiol | Estradiol | 22 | 11 |
| Lactulose | Lactulose | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Invokana | Canagliflozin | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Fluocinonide | Fluocinonide | 20 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Praluent Pen | Alirocumab | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $169.28 · 9 records | Exact Sciences Corporation | CREON, Cologuard Collection Kit, FREESTYLE LIBRE 3, LEQVIO, LINZESS | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error